A Phase 1 interventional study of HDDO-1756 and HDDO-17561/HDDO-17562 in Hyperlipidemias, sponsored by Hyundai Pharmaceutical Co., LTD.. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-17.
Sponsored by Hyundai Pharmaceutical Co., LTD. · Phase 1, Interventional, and Treatment
For healthy adult volunteers, safety and pharmacokinetic properties are compared between the two formulations in the case of HDDO-1756 alone administration and HDDO-17561/HDDO-17562 combined administration.
821 studies on the registry are indexed under Hyperlipidemias; 105 are open to participants now.
This study's enrollment of 56 is below the median of 87 across 691 interventional studies indexed under Hyperlipidemias.
Browse Hyperlipidemias studies →Hyundai Pharmaceutical Co., LTD. is the lead sponsor of 11 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
A person who weighs more than 50.0 kg and has a BMI of 18.0 kg/m2 or less and 30.0 kg/m2 or less.
☞ BMI (kg/m2) = Weight (kg) / {Long (m)}2
Exclusion Criteria:
Drug: HDDO-1756
Drug: HDDO-17561/HDDO-17562
single dose
single dose
pharmacokinetic evaluation variables
Cmax
Time frame: 0~96 hours
pharmacokinetic evaluation variables
AUC
Time frame: 0~96 hours
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hyundai Pharmaceutical Co., LTD.